These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 33534065)

  • 1. Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature.
    Meini S; Viaggi B; Tascini C
    Infection; 2021 Jun; 49(3):411-421. PubMed ID: 33534065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
    Nordmann P; Bouvier M; Poirel L
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
    Sadek M; Bosch Duran J; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
    Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
    Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
    Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
    Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
    Stock I
    Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
    Bassetti M; Giacobbe DR; Robba C; Pelosi P; Vena A
    Curr Opin Infect Dis; 2020 Dec; 33(6):474-481. PubMed ID: 33060469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance.
    Carpenter J; Neidig N; Campbell A; Thornsberry T; Truex T; Fortney T; Zhang Y; Bush K
    J Antimicrob Chemother; 2019 Nov; 74(11):3260-3263. PubMed ID: 31430370
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
    Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
    Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.